Results 41 to 50 of about 183,209 (216)

Interplay between circadian and other transcription factors—Implications for cycling transcriptome reprogramming

FEBS Letters, EarlyView.
This perspective highlights emerging insights into how the circadian transcription factor CLOCK:BMAL1 regulates chromatin architecture, cooperates with other transcription factors, and coordinates enhancer dynamics. We propose an updated framework for how circadian transcription factors operate within dynamic and multifactorial chromatin landscapes ...
Xinyu Y. Nie, Jerome S. Menet
wiley   +1 more source

HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes [PDF]

, 2010
Histone deacetylases (HDACs) regulate the acetylation of histones in the control of gene expression. Many non-histone proteins are also targeted for acetylation, including TGF-ß signalling pathway components such as Smad2, Smad3 and Smad7. Our studies in
Andrew D. Rowan, Bain, Cao, Chen, Chen, Cho, Clayton, David A. Young, de Ruijter, Denker, Dennler, Derynck, Dylan R. Edwards, Fecteau, Gary J. Litherland, Ghosh, Glenisson, Glozak, Gottlicher, Gregoretti, Gurvich, Hazzalin, Horowitz, Ian M. Clark, Khan, Kobayashi, Kouzarides, Kuang, Kwak, Le Pabic, Le Pabic, Lee, Leon Pybus, Li, Lien, Litherland, Mahlknecht, Matt J. Barter, Michaelis, Rombouts, Shi, Tim E. Cawston, Togi, Tu, Vannini, Verdin, Wang, Whitmarsh, Wrana, Xu, Yamaguchi, Yoshikawa, Young, Yu, Zhang   +54 more
core   +1 more source

The role of histone modifications in transcription regulation upon DNA damage

FEBS Letters, EarlyView.
This review discusses the critical role of histone modifications in regulating gene expression during the DNA damage response (DDR). By modulating chromatin structure and recruiting repair factors, these post‐translational modifications fine‐tune transcriptional programmes to maintain genomic stability.
Angelina Job Kolady, Siyao Wang
wiley   +1 more source

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

Experimental Hematology & Oncology
Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S.
Jingjing Pu, Ting Liu, Xuzhen Wang, Amit Sharma, Ingo G. H. Schmidt-Wolf, Liping Jiang, Jian Hou   +6 more
doaj   +1 more source

Design, Synthesis and Cytotoxicity Study of Primary Amides as Histone Deacetylase Inhibitors

Iraqi Journal of Pharmaceutical Sciences, 2019
Primary amide derivatives as histone deacetylase inhibitors (HDACIs) are very rare. This paper describes the synthesis of primary amide derivatives (compounds 6 and 7) that have the requirements to be histone deacetylase inhibitors of the zinc-binding ...
Duraid Al-Amily, Mohammed H. Mohammed
doaj   +1 more source

Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells

Frontiers in Cell and Developmental Biology, 2020
Sorafenib resistance and tumor metastasis account for poor outcome of hepatocellular carcinoma (HCC). Histone deacetylase 11 (HDAC11) has been reported to exert oncogenic effects in several types of human cancer, but its specific functions and detailed ...
Wenlong Wang, Bisha Ding, Weiyang Lou, Shengyou Lin   +3 more
doaj   +1 more source

HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal [PDF]

, 2018
Peritoneal fibrosis is a pathological alteration of the peritoneal membrane occurring in a variety of conditions including peritoneal dialysis (PD), post-surgery adhesions and peritoneal metastases.
Battistelli, Cecilia, Bordoni, Veronica, DE TURRIS, Valeria, Domenici, Alessandro, Mai, Antonello, Manzione, Andrea, Mene', Paolo, Moioli, Alessandra, Noce, Valeria, Palladino, Marco, Rossi, Lucia, Strippoli, Raffaele, Tripodi, Marco, Valente, Sergio, Zwergel, Clemens   +14 more
core   +1 more source

Histone deacetylases and cancer [PDF]

Molecular Oncology, 2012
Reversible acetylation of histone and non‐histone proteins is one of the most abundant post‐translational modifications in eukaryotic cells. Protein acetylation and deacetylation are achieved by the antagonistic actions of two families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs).
Bruna, Barneda-Zahonero, Maribel, Parra
openaire   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Repressing iron overload ameliorates central post-stroke pain via the Hdac2-Kv1.2 axis in a rat model of hemorrhagic stroke

Neural Regeneration Research
Thalamic hemorrhage can lead to the development of central post-stroke pain. Changes in histone acetylation levels, which are regulated by histone deacetylases, affect the excitability of neurons surrounding the hemorrhagic area.
He Fang, Mengjie Li, Jingchen Yang, Shunping Ma, Li Zhang, Hongqi Yang, Qiongyan Tang, Jing Cao, Weimin Yang   +8 more
doaj   +1 more source